Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
4D Molecular Therapeutics, Inc. - Common Stock
(NQ:
FDMT
)
9.195
+0.335 (+3.78%)
Streaming Delayed Price
Updated: 10:17 AM EST, Feb 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 4D Molecular Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
4DMT Announces New Employment Inducement Grants
January 17, 2026
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Provides Company Update and Anticipated Development Milestones for 2026
January 07, 2026
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
December 17, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
December 12, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 08, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in 8th Annual Evercore Healthcare Conference
November 20, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Appoints Kristian Humer as Chief Financial Officer
November 17, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
November 14, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 10, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Jefferies 2025 London Healthcare Conference
November 06, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
November 06, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
November 06, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
October 30, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
October 17, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
October 14, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
October 13, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
September 12, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
September 02, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
August 25, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
August 15, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
August 11, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 06, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
July 31, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
July 24, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
July 11, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
July 02, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
May 28, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces New Employment Inducement Grants
May 16, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
May 08, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
May 05, 2025
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
